Inside the research
Cytek Biosciences, Inc.
CTKB Research profile · latest available data
Price overview
$5.65
▼ -0.08 (-1.4%)
| 52w hi | $5.88 |
|---|---|
| 52w lo | $3.36 |
| Vol | 1.49M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.01
| Short | +0.25 |
|---|---|
| Medium | +0.10 |
| Long | -0.64 |
computed 2026-09-27
Key fundamentals
Cytek Biosciences, Inc.
Healthcare · Medical Devices
| Market cap | $734.41M |
|---|---|
| Enterprise value | $498.86M |
| Forward P/E | 80.71x |
| EV / EBITDA | -12.55x |
| P / S (ttm) | 3.55x |
| Profit margin | -39.0% |
| Return on equity | -23.0% |
| Revenue growth | +5.6% |
| Debt / equity | 8.22 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.16 | |
| Sector | +0.08 | |
| Technical | +0.20 | |
| Earnings | +0.00 | |
| Sentiment | -0.11 |
macro × 1.00 · 2026-09-27
Business overview
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Risk Metrics
| Beta vs SPX | 1.24 |
|---|---|
| Corr SPX | 0.30 |
| Annual vol | 65.7% |
| Annual ret | +26.3% |
| Sharpe | 0.40 |
| Max DD | -67.3% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-07-15 | Officer / Director Change | read |
| 2026-06-25 | Officer / Director Change | read |
| 2026-06-16 | Shareholder Vote | read |
| 2026-06-02 | Officer / Director Change | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-13 | Earnings Release, Exhibits | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-08-06 | Earnings Release, Exhibits | read |
| 2025-06-24 | Shareholder Vote | read |
| 2025-05-08 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Yan Ming | Director, Officer, CHIEF | Gift | 135.89K | — |
| 2026-06-10 | Ball Jack | Director | Option exercise | 43.97K | — |
| 2026-06-10 | Imper Vera | Director | Option exercise | 43.97K | — |
| 2026-06-10 | NEFF DEBORAH J | Director | Option exercise | 43.97K | — |
| 2026-06-10 | Holder Michael | Director | Option exercise | 43.97K | — |
| 2026-05-18 | Holder Michael | Director | Option exercise | 1.45K | — |
| 2026-05-18 | Chin Richard | Director | Option exercise | 6.11K | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 96.0% |
| HHI | 4,430 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Millennium Management | $41.37M | 9.34M |
| State Street Corp | $11.37M | 2.57M |
| AQR Capital Management | $3.61M | 813.97K |
| Citadel Advisors | $3.20M | 721.47K |
| Renaissance Technologies | $2.93M | 661.30K |
| Fidelity / FMR LLC | $2.23M | 504.38K |
| Capital Research / Capital World | $393.89K | 88.91K |
| T. Rowe Price Group | $449 | 101.20K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2021–2025 · 5 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $201.49M | +21.4% | |
| Gross profit | $111.11M | +8.9% | |
| Operating income | -$40.38M | -18.1% | |
| Net income | -$66.54M | -6.4% | |
| Cash from ops | $5.28M | +3.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $5.71 | $5.75 | $5.57 | $5.65 | 1.49M |
| Sep 24 | $5.64 | $5.83 | $5.48 | $5.73 | 1.60M |
| Sep 23 | $5.73 | $5.85 | $5.63 | $5.68 | 1.26M |
| Sep 22 | $5.29 | $5.84 | $5.26 | $5.71 | 3.78M |
| Sep 21 | $5.32 | $5.32 | $5.20 | $5.28 | 1.25M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →